Soligenix Granted Orphan Drug Designation for Vaccine to Treat MARV Infection
Life Sciences On Apr 15, 2024 Soligenix, Inc., the Princeton-based late-stage biopharmaceutical company focused on treating rare diseases where there is an unmet medical need, announced that the Office of Orphan Products Development of the United States (U …